

08-23-2002
102200244

Form PTO-1595
(Rev. 03/01)
OMB No. 0651-0027 (exp. 5/31/200)
Tab settings

ET U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
1115303-0004

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
AstraZeneca AB
8-16-02
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: Medivir AB
Internal Address: _____
Street Address: Lunastigen 7
S-141 44 Huddinge
SWEDEN
City: _____ State: _____ Zip: _____
Additional name(s) & address(es) attached? Yes No

OFFICE OF PUBLIC RECORDS
2002 AUG 16 PM 2:54
FINANCE SECTION

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other _____
Execution Date: August 7, 2001

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No.(s) _____
B. Patent No.(s) 6,068,860
Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: White & Case LLP
Internal Address: _____
Street Address: Patent Department
1155 Avenue of the Americas
City: New York State: NY Zip: 10036

6. Total number of applications and patents involved: 1
7. Total fee (37 CFR 3.41).....\$40.00
 Enclosed
 Authorized to be charged to deposit account
8. Deposit account number:
23-1703
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.
Richard J. Sterner, Reg. No. 35,372 Richard J. Sterner August 12, 2002
Name of Person Signing Signature Date

Total number of pages including cover sheet, attachments, and documents: 5

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

08/22/2002 610N11 00000221 231703 6068860
01 FC:581 40.00 CH

PATENT
REEL: 013203 FRAME: 0674

ASSIGNMENT

AstraZeneca AB, S-151 85 Södertälje, Sweden ("AstraZeneca"), owner of rights, title and interest in and to the inventions disclosed in the patents and patent applications listed below by virtue of previous assignments executed by the inventors, does hereby assign and transfer, in accordance with the provisions of the Development and License Agreement of 20 February, 1998 between Medivir AB, Lunastigen 7, S-141 44 Huddinge, Sweden ("Medivir") and AstraZeneca to Medivir AstraZeneca's entire right, title and interest in all countries throughout the world in and to any and all inventions disclosed in the following patents and patent applications and including the right to claim Convention priority from PCT/SE95/00113 (A1350), PCT/SE95/00112 (A1351) and PCT/SE95/00114 (A1352):

A1350

COUNTRY	APPLN. NO.	APPLN. DATE	PATENT NO.	PATENT TERM
United States	08/605057	02.02.1996	6117857	02.02.2016

A1351

COUNTRY	APPLN. NO.	APPLN. DATE	PATENT NO.	PATENT TERM
Austria*	96902556.8	02.02.1996		
Belgium*	96902556.8	02.02.1996		
Denmark*	96902556.8	02.02.1996		
EPO	96902556.8	02.02.1996		
France*	96902556.8	02.02.1996		
Germany*	96902556.8	02.02.1996		
Gr. Britain*	96902556.8	02.02.1996		
Greece*	96902556.8	02.02.1996		
Ireland*	96902556.8	02.02.1996		
Italy*	96902556.8	02.02.1996		
Japan	524188/96	02.02.1996		
Latvia ¹¹	96902556.8	02.02.1996		
Liechtenstein*	96902556.8	02.02.1996		

Lithuania ¹¹	96902556.8	02.02.1996		
Luxembourg*	96902556.8	02.02.1996		
Monaco*	96902556.8	02.02.1996		
Netherlands*	96902556.8	02.02.1996		
Slovenia ¹¹	96902556.8	02.02.1996		
Spain*	96902556.8	02.02.1996		
Sweden*	96902556.8	02.02.1996		
Switzerland*	96902556.8	02.02.1996		
United States	08/602784	02.02.1996	6068860	02.02.2016

A1352

COUNTRY	APPLN. NO.	APPLN. DATE	PATENT NO.	PATENT TERM
Algeria	96007	10.01.1996		
Argentina	960101279	05.02.1996		
Australia	46821/96	02.02.1996	716809	02.02.2016
Austria*	96902557.6	02.02.1996		
Belgium*	96902557.6	02.02.1996		
Canada	221138902.02.1996			
China	96192868.9	02.02.1996		
Croatia	P960034A	23.01.1996		
Denmark*	96902557.6	02.02.1996		
Egypt	100/96	05.02.1996		
EPO	96902557.6	02.02.1996		
Finland	973243	02.02.1996		
France*	96902557.6	02.02.1996		
Germany*	96902557.6	02.02.1996		
Gr. Britain*	96902557.6	02.02.1996		
Greece*	96902557.6	02.02.1996		
Hong Kong	98103634.9	29.04.1998		
India	108/DEL/96	17.01.1996		
Indonesia	P-960165	23.01.1996		
Ireland*	96902557.6	02.02.1996		
Israel	116913	26.01.1996		
Italy*	96902557.6	02.02.1996		
Japan	524189/96	02.02.1996		
Korea, South	97/705356	02.02.1996		
Kuwait	PA/20/96	03.02.1996		
Latvia ¹¹	96902557.6	02.02.1996		

Libya	407/96	06.02.1996		
Liechtenstein*	96902557.6	02.02.1996		
Lithuania ¹⁾	96902557.6	02.02.1996		
Luxembourg*	96902557.6	02.02.1996		
Malaysia	PI9600423	06.02.1996		
Monaco*	96902557.6	02.02.1996		
Morocco	PV2415505.02.1996	23800		05.02.2016
Netherlands*	96902557.6	02.02.1996		
New Zealand	301407	02.02.1996	301407	02.02.2016
Nigeria	45/96	05.02.1996	RP12782	05.02.2016
Norway	973612	02.02.1996		
Pakistan	059/96	01.02.1996	135164	01.02.2012
Philippines	52285	02.02.1996		
Portugal*	96902557.6	02.02.1996		
Saudi Arabia	96160590	10.02.1996		
Slovenia ¹⁾	96902557.6	02.02.1996		
South Africa	96/052723.01.1996	96/0527		23.01.2016
Spain*	96902557.6	02.02.1996		
Sweden*	96902557.6	02.02.1996		
Switzerland*	96902557.6	02.02.1996		
Taiwan	85100236	10.01.1996		
Thailand	029929	05.02.1996		
Tunisia	SN9602405.02.1996			
United States	08/612847	02.02.1996		
Yugoslavia	P-0072/96	06.02.1996		


* included in the EPO patent application

1) registration of EP patent when granted

including any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part and divisionals thereof, and any substitute applications therefor.

Executed this ... 7 ... day of ... August ... , 2001.


ASTRAZENECA AB (publ)



Per From
President &
Chief Executive Officer

ACKNOWLEDGEMENT OF ASSIGNEE:

Medivir hereby acknowledges the foregoing executed
Assignment.


Jonas Frick
President &
Chief Executive Officer